Hypericin

Published

dm+d

Unassigned

New Medicines

VIMRxyn, HyBryte (US) Cutaneous T-cell lymphoma (CTCL)

Information

VIMRxyn, HyBryte (US)
New molecular entity
Soligenix
Soligenix

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

First-in-class synthetic photosensitiser with anti-proliferative effects on activated normal human lymphoid cells and inhibits growth of malignant T-cells [3,4]. Utilises safe visible fluorescent light for activation.
Cutaneous T-cell lymphoma (CTCL) affects approximately 0.1 to 0.5 in 10,000 people in the EU. White people have a higher risk than black and Asian people and the median age at presentation is >50 years. Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced [1,2].
Cutaneous T-cell lymphoma (CTCL)
Topical

Evidence based evaluations